

Quarterly Results and Investor Conference Call Notification

Brisbane, **Australia**, **25 July 2022** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today advises that it will release its Quarterly Activities Report and Appendix 4C for the fourth quarter on Wednesday, 27 July 2022.

Shareholders are invited to join a conference call hosted by Tony Keating, CEO and Managing Director on Wednesday, 27 July 2022 at 10:00am Australian Eastern Standard Time (AEST).

Shareholders can pre-register for the conference call by following the link below. You will receive a calendar notification with dial-in details and a PIN to access the call.

https://s1.c-conf.com/diamondpass/10023601-s319fm.html

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating CEO and Managing Director +61 430 180 659 tony@resapphealth.com.au Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.